Pediatrix Medical Group Reports $476.2 Million Revenue in Q1 2026, 3.9% Increase Year-Over-Year

Pediatrix Medical Group, Inc. reported a net revenue of $476.2 million for the first quarter of 2026, reflecting a 3.9% increase from $458.4 million in the same period of 2025. The growth in revenue was primarily driven by an increase in same-unit revenue, which rose by $12.1 million, or 2.8%, attributed to improved collection activities and increased administrative fees from hospital partners. The company’s income from operations also saw a significant increase, rising 29.8% to $41.7 million, compared to $32.1 million in the prior year, resulting in an operating margin of 8.7%, up from 7.0%.

In terms of expenses, total operating expenses increased to $434.5 million from $426.3 million year-over-year. Notably, practice salaries and benefits rose by $8.7 million, or 2.6%, primarily due to increased clinical compensation. General and administrative expenses also increased by $1.7 million, largely due to higher incentive compensation expenses. The company reported a net income of $29.6 million, or $0.36 per diluted share, compared to $20.7 million, or $0.24 per diluted share, in the previous year.

Pediatrix made a strategic acquisition of a maternal-fetal medicine practice for $7.9 million in March 2026, which is expected to enhance its national network of physician practices. This acquisition added $7.5 million in tax-deductible goodwill and is part of the company's ongoing strategy to expand its services in women’s and children’s healthcare. The company also reported a decrease in cash and cash equivalents to $205.8 million from $375.2 million at the end of 2025, largely due to increased current liabilities and cash used in operations.

Operationally, the company reported a decrease in days sales outstanding (DSO) to 42.5 days, down from 47.6 days a year earlier, indicating improved cash collection efficiency. However, cash used in operating activities increased to $129.5 million from $116.1 million, primarily due to higher working capital needs. The company’s total liabilities decreased to $1.2 billion from $1.4 billion, with a notable reduction in accounts payable and accrued expenses.

Looking ahead, Pediatrix anticipates that its current cash reserves and operational cash flow will be sufficient to meet its working capital needs, fund acquisitions, and support its share repurchase programs over the next 12 months. The company remains focused on enhancing its service offerings and improving operational efficiencies, despite ongoing challenges in the healthcare landscape, including reimbursement pressures and regulatory changes.